Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one...
Fosun: Foreign Media Reports about “Regulatory Authorities Asking Banks to Examine their Exposure to Fosun” are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun has sought confirmation from regulatory authorities through multiple channels. The China Banking and...
Introducing Crown Aesthetics’ International Educational Program for SkinPen® Precision Customers
Crown Aesthetics Elevates its Commitment to Customer Education and Training DALLAS, Sept. 14, 2022 /PRNewswire/ -- Crown Aesthetics ("Crown"), a division of Crown Laboratories, Inc., announced today that its direct United Kingdom and Ireland ("UKI") team will now offer all UK & Ireland SkinPen Precision customers with an opportunity to receive internationally...
Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Sept. 14, 2022 /PRNewswire/ --Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from U.S. Food and Drug Administration (FDA). Gremlin1, a member of the TGF-β super...
Nippon Express Obtains GDP Certification of Compliance with WHO Standards at East Japan Pharmaceutical Center
- Dedicated Pharmaceutical Logistics Facility Offers Storage and Transport in Two Temperature Ranges - TOKYO, Sept. 14, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereafter "Nippon Express"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) certification for its East Japan Pharmaceutical Center (Kuki City, Saitama Prefecture), effective July 29, evidencing its compliance with...
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a Non-Executive Director to the board. AROA's products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial...
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 14, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer. Radiopharm Ventures brings together MD Anderson's innovative and...
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 months, among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS was 12.88 months. 26 patients with metastatic NSCLC who failed to...
GBB Lands USD 15M Pre-Series B Funding Led by Tiger Jade Capital
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of its USD 15M Pre-series B funding led by Tiger Jade Capital (hereinafter referred to as "Tiger Jade"). The funding was oversubscribed and upsized with participation from one of the world's top life science MNCs, AEF Greater...
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022
2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line（1L）treatment for advanced NSCLC patients In 87 efficacy evaluable patients, confirmed ORR was 46%. Median OS in non-squamous NSCLC and squamous NSCLC were 27.2 months and 26.6 months respectively. The phase III clinical study of...
